Mibefradil

Mibefradil

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a607007
Routes of administration	Oral
ATC code	C08CX01 (WHO)
Legal status
Legal status	Withdrawn from market
Pharmacokinetic data
Bioavailability	70 %
Protein binding	> 99 %
Metabolism	Hepatic
Elimination half-life	17-25 h
Identifiers
IUPAC name (1S,2S)-2-(2-((3-(1H-benzo[d]imidazol-2-yl)propyl) (methyl)amino)ethyl)-6-fluoro-1-isopropyl- 1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate
CAS Number	116644-53-2 Y
PubChem CID	60662
DrugBank	DB01388 N
ChemSpider	54673 N
UNII	27B90X776A
KEGG	D08217 Y
ChEMBL	ChEMBL45816 N
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C29H38FN3O3
Molar mass	495.63 g/mol
3D model (JSmol)	Interactive image
Melting point	128 °C (262.4 °F) (dihydrochloride salt)
SMILES CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F
InChI InChI=1S/C29H38FN3O3/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28,36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26/h5-6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32)/t28-,29-/m0/s1 N Key:HBNPJJILLOYFJU-VMPREFPWSA-N N
NY (what is this?)  (verify)

WikiDoc Resources for Mibefradil
Articles
Most recent articles on Mibefradil Most cited articles on Mibefradil Review articles on Mibefradil Articles on Mibefradil in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mibefradil Images of Mibefradil Photos of Mibefradil Podcasts & MP3s on Mibefradil Videos on Mibefradil
Evidence Based Medicine
Cochrane Collaboration on Mibefradil Bandolier on Mibefradil TRIP on Mibefradil
Clinical Trials
Ongoing Trials on Mibefradil at Clinical Trials.gov Trial results on Mibefradil Clinical Trials on Mibefradil at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mibefradil NICE Guidance on Mibefradil NHS PRODIGY Guidance FDA on Mibefradil CDC on Mibefradil
Books
Books on Mibefradil
News
Mibefradil in the news Be alerted to news on Mibefradil News trends on Mibefradil
Commentary
Blogs on Mibefradil
Definitions
Definitions of Mibefradil
Patient Resources / Community
Patient resources on Mibefradil Discussion groups on Mibefradil Patient Handouts on Mibefradil Directions to Hospitals Treating Mibefradil Risk calculators and risk factors for Mibefradil
Healthcare Provider Resources
Symptoms of Mibefradil Causes & Risk Factors for Mibefradil Diagnostic studies for Mibefradil Treatment of Mibefradil
Continuing Medical Education (CME)
CME Programs on Mibefradil
International
Mibefradil en Espanol Mibefradil en Francais
Business
Mibefradil in the Marketplace Patents on Mibefradil
Experimental / Informatics
List of terms related to Mibefradil

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers.

It is nonselective.

On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications.

Synthesis

Mibefradil synthesis